Merck said results from a Phase III clinical study showed its investigational allergy immunotherapy tablet reduced ragweed allergy symptoms in adults.
WSJ.com: What's News US, Wall Street Journal: Home US
Mon, 03/05/2012 - 8:52am
Merck said results from a Phase III clinical study showed its investigational allergy immunotherapy tablet reduced ragweed allergy symptoms in adults.